Skip to main content

Table 1 Characteristics of all NET patients included in this study for Lu-177-Octreotate therapy

From: Patient-specific image-based bone marrow dosimetry in Lu-177-[DOTA0,Tyr3]-Octreotate and Lu-177-DKFZ-PSMA-617 therapy: investigation of a new hybrid image approach

Octreotate P1 P2 P3 P4 P5
Sex M M F F F
Age 68 66 61 47 73
Activity investigated cycle [MBq] 7654 7425 7420 7409 7410
Diagnosis NET small intestine NET NET terminal ileum NET pancreas NET stomach
Metastases (PET/CT)
 - Extend Medium Medium Medium Medium Medium
 - Type (VIS = visceral, LYM = lymph, OSS = osseous) Mainly VIS (liver), LYM Mainly LYM, VIS (liver) Mainly VIS (liver), LYM, OSS Mainly LYM, VIS (liver and other) Mainly VIS (liver), OSS
Proliferation index Ki67 3–4% Ki67 5–10% Ki67 1% Ki67 10% Ki67 10%
Pre-therapies SSA-analogues Interferon alpha Hemicolectomy, SSA-analogues, radioembolization Chemotherapy (stroptozotocin/5-FU, dacarbazapin, capecitabin/Te-modal) SSA-analogues, bisphosphonate therapy
Blood pre-therapy
 - Leukocytes [G/l] 7.76 10.4 3.79 3.93 10.2
 - Erythrocytes [T/l] 4.58 4.50 4.43 3.73 4.42
 - Thrombocytes [G/l] 207 294 297 177 303
 - Haematocrit 0.421 0.442 0.373 0.341 0.399